The antiserum was produced against synthesized peptide derived from human PLK1 around the phosphorylation site of Ser137. AA range:103-152

Phospho-Plk1 (S137) Polyclonal Antibody detects endogenous levels of Plk1 protein only when phosphorylated at S137.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):RRsLL

PLK1

Serine/threonine-protein kinase PLK1

PLK1 ;
PLK ;
Serine/threonine-protein kinase PLK1 ;
Polo-like kinase 1 ;
PLK-1 ;
Serine/threonine-protein kinase 13 ;
STPK13

The Ser/Thr protein kinase encoded by this gene belongs to the CDC5/Polo subfamily. It is highly expressed during mitosis and elevated levels are found in many different types of cancer. Depletion of this protein in cancer cells dramatically inhibited cell proliferation and induced apoptosis; hence, it is a target for cancer therapy. [provided by RefSeq, Sep 2015],

Catalytic activity:ATP + a protein = ADP + a phosphoprotein.,developmental stage:Accumulates to a maximum during the G2 and M phases, declines to a nearly undetectable level following mitosis and throughout G1 phase, and then begins to accumulate again during S phase.,enzyme regulation:Activated by serine and threonine phosphorylation.,Function:Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of APC/C inhibitors, and the regulation of mitotic exit and cytokinesis.,induction:By growth-stimulating agents.,PTM:Autophosphorylation and phosphorylation of Ser-137 are not significant events during activation of PLK1 in M phase.,PTM:Catalytic activity is enhanced by phosphorylation of Thr-210 and/or Ser-137.,similarity:Belongs to the protein kinase superfamily.,similarity:Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. CDC5/Polo subfamily.,similarity:Contains 1 protein kinase domain.,similarity:Contains 2 POLO box domains.,subunit:Interacts with CEP170 and EVI5. Interacts and phosphorylates ERCC6L. Interacts with FAM29A.,tissue specificity:Placenta and colon.,

Nucleus. Chromosome, centromere, kinetochore. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Cytoplasm, cytoskeleton, spindle . Midbody . localization at the centrosome starts at the G1/S transition (PubMed:24018379). During early stages of mitosis, the phosphorylated form is detected on centrosomes and kinetochores. Localizes to the outer kinetochore. Presence of SGO1 and interaction with the phosphorylated form of BUB1 is required for the kinetochore localization. Localizes onto the central spindle by phosphorylating and docking at midzone proteins KIF20A/MKLP2 and PRC1. Colocalizes with FRY to separating centrosomes and spindle poles from prophase to metaphase in mitosis, but not in other stages of the cell cycle. Localization to the centrosome is required for S phase progression (PubMed:24018379). Colocalizes with HSF1 at the spindle poles during prometaphase (PubMed:18794143). .

Placenta and colon.

>>FoxO signaling pathway ;
>>Cell cycle ;
>>Oocyte meiosis ;
>>Progesterone-mediated oocyte maturation